睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of DEG6498 in Participants With Solid Tumors

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京高博医院Beijing GoBroad Hospital北京医院页面
  2. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  3. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07244835,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Active or concurrent malignancy requiring treatment (including both systemic therapy and radiotherapy) within 14 days or 5 half lives (whichever is shorter) prior to the first dose of study drug, or received antibody therapy within 28 days

    排除标准第 4 条

  3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    入选标准第 10 条

  4. Presence of at least 1 measurable lesion according to RECIST v1.1 .

    入选标准第 9 条

  5. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome, or active HBV or HCV infection.

    排除标准第 8 条

  6. If female, must be postmenopausal, or surgically sterile, or agree to highly effective contraceptive measures to prevent pregnancy throughout treatment period and within 30 days of last study drug treatment

    入选标准第 3 条

    If male, must agree to inform and ensure their female partners to use highly effective contraception measures to prevent pregnancy, and to refrain from donating sperm while on study drug and for at least 30 days following DEG6498 discontinuation

    入选标准第 5 条

    Pregnant or breastfeeding women

    排除标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07244835,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures
  2. Male and female older than or equal to 18 years of age at the time signing the informed consent form (ICF)
  3. If female, must be postmenopausal, or surgically sterile, or agree to highly effective contraceptive measures to prevent pregnancy throughout treatment period and within 30 days of last study drug treatment
  4. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests (1 serum test required) as verified by the investigator prior to starting study drug
  5. If male, must agree to inform and ensure their female partners to use highly effective contraception measures to prevent pregnancy, and to refrain from donating sperm while on study drug and for at least 30 days following DEG6498 discontinuation
  6. Patients with advanced solid tumors, who have failed standard therapies, or for whom no standard therapy exists
  7. Part 1: Advanced solid tumor patients
  8. Part 2: Patients with BRAF mutation positive tumors and HCC
  9. Presence of at least 1 measurable lesion according to RECIST v1.1 .
  10. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

排除标准:Exclusion Criteria:

  1. Participant has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study, puts the participant at unacceptable risk if he/she were to participate in the study
  2. Participant has a condition that confounds the ability for interpret data from the study
  3. Pregnant or breastfeeding women
  4. Active or concurrent malignancy requiring treatment (including both systemic therapy and radiotherapy) within 14 days or 5 half lives (whichever is shorter) prior to the first dose of study drug, or received antibody therapy within 28 days
  5. Symptomatic CNS metastases which are neurologically unstable, or CNS metastases requiring local CNS directed therapy, or increasing doses of corticosteroids within 2 weeks of first dose of study treatment.
  6. Clinically significant cardiovascular disease
  7. Known active or chronic infection that requires systemic therapy within 2 weeks of first dose of study drug
  8. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome, or active HBV or HCV infection.

引自 ClinicalTrials.gov, NCT07244835, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07244835,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07244835